anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a compound of an diclofenac or the halo-diclofenac local membrane forming gel, which comprises the components of the following weight percentages comprising  0.5 percentage to 7 percentage of alkyl cellulose,  1 percentage to 10 percentage of etherifying agent , 0.5 percentage to 5 percentage of cross linking agent, 75 percentage to 90 percentage of dissolvent, 0.1percentage to 3 percentage of diclofenac or the halo-diclofenac. The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is C<SUB>n</SUB>H<SUB>2n+2-m-l</SUB>(OH)<SUB>m</SUB>(COOH)<SUB>l</SUB>. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. 1 is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the diclofenac or the halo-diclofenac local membrane forming gel is applied for relieving the local pain and inflammation of the organism tissue. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of formulations of the diclofenac or the halo-diclofenac in the present technique, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has properties of long maintenance time and slow releasing of the medicine.
Immediately after the completion of standardized exercise ThermaCare HeatWraps will be applied on each leg centered over the quadriceps and lying longitudinally over the muscle for 8 hours. The application of a new ThermaCare HeatWraps will be repeated in the same manner, for 8 hours each, at 24 and 48 hours after exercise (i.e., 3 applications in total).
INTRODUCTION: The Kansas City Cardiomyopathy Questionnaire (KCCQ), Seattle Angina Questionnaire (SAQ), and Minnesota Living with Heart Failure Questionnaire (MLHFQ) are widely used non-preference-based instruments that measure health-related quality of life (QOL) in people with heart disease. However, currently it is not possible to estimate quality-adjusted life-years (QALYs) for economic evaluation using these instruments as the summary scores produced are not preference-based. The MacNew-7D is a heart disease-specific preference-based instrument. This study provides different mapping algorithms for allocating utility scores to KCCQ, MLHFQ, and SAQ from MacNew-7D to calculate QALYs for economic evaluations.
METHODS: The study included 493 participants with heart failure or angina who completed the KCCQ, MLHFQ, SAQ, and MacNew-7D questionnaires. Regression techniques, namely, Gamma Generalized Linear Model (GLM), Bayesian GLM, Linear regression with stepwise selection and Random Forest were used to develop direct mapping algorithms. Cross-validation was employed due to the absence of an external validation dataset. The study followed the Mapping onto Preference-based measures reporting Standards checklist.
RESULTS: The best models to predict MacNew-7D utility scores were determined using KCCQ, MLHFQ, and SAQ item and domain scores. Random Forest performed well for item scores for all questionnaires and domain score for KCCQ, while Bayesian GLM and Linear Regression were best for MLHFQ and SAQ domain scores. However, models tended to over-predict severe health states.
CONCLUSION: The three cardiac-specific non-preference-based QOL instruments can be mapped onto MacNew-7D utilities with good predictive accuracy using both direct response mapping techniques. The reported mapping algorithms may facilitate estimation of health utility for economic evaluations that have used these QOL instruments.
Frozen serum leftovers. A first sample was collected, and the US licensed and CE-marked vaccination series administered. A second sample was collected four (4) to ten (10) weeks after the complete vaccination series has been administered according to vaccine dosing instructions.
FIELD: medicine. SUBSTANCE: method involves introducing 0.8-1% sodium sulfate solution into the blood. The solution is exposed to electrochemical oxidation in anode chamber of aperture electrolyzer for 50-70 min on titanium anode promoted with platinum under its 1.0-1.5 mg/cm contents on the anode surface and current density of 0.1-2.0 A/dm. Then the solution is brought to pH=6.5-7.5. EFFECT: prolonged action of the solution. 2 tbl
The invention relates to a Chinese-western compound combination for livestock, which is used for relieving exterior and interior syndrome, bringing down a fever, relieving pain and diminishing inflammations and belongs to the field of Chinese veterinary medicines. Medicine ingredients of the combination consist of radix bupleuri, ephedra, cassia twig, peach kernels, licorice roots and analgin. The combination can be prepared into preparation formulations such as injection, oral liquid, granular formulation, powder and the like. The fever abatement effect of the combination is better than that of chemical drug ephedrine preparation or pure traditional Chinese medicine preparation. In addition, the Chinese-western compound combination has the advantages that the Chinese-western compound combination takes effect fast, and fever of the livestock cannot recur easily. Besides, the Chinese-western compound combination has an excellent treatment effect for various high fever diseases of the livestock.
Restless legs syndrome (RLS), or Willis-Ekbom Disease, is a neurologic disorder causing unpleasant sensations and an urge to move the legs when the person is at rest. The sensations are relieved by movement. Loss of sleep associated with RLS can cause extreme fatigue, affecting concentration, which may produce anxiety and depression, resulting in a poor quality of life. Prevalence in the general population is 5% to 10%. In approximately 3%, symptoms are so severe that treatment is sought. Potent drugs, such as opioids, central nervous system depressants, anticonvulsants, and dopamine agonists have been used to ease symptoms, each with several side effects.

Anecdotal evidence suggested that pressure on specific foot muscles decreases symptoms of moderate to severe primary restless legs syndrome. In the RESTIFFIC™ study, patients served as their own negative controls, wearing the RESTIFFIC™ devices intermittently, while completing surveys related to RLS throughout the study. Physicians also completed surveys related to quality of life. Meta-analysis was used to compare RESTIFFIC™ to historic reports of ropinirole and placebo pill. Demographics, disease severity,inclusion/exclusion criteria, assessment tools were similar among studies.
Malaria remains one of the world's greatest childhood killers and is a substantial obstacle to social and economic development in the tropics. The overwhelming bulk of the world's malaria burden rests upon the population of sub-Saharan Africa because of the unique coincidence of expanding human populations, weak health systems, the world's most effective vector mosquito species and environmental conditions ideal for transmission. At the start of the new millennium malaria is still deeply entrenched in Africa and effective malaria control is under threat from the inexorable spread of parasite strains resistant to antimalarial drugs and the emergence of mosquitoes resistant to the pyrethroid insecticides used to impregnate bednets. Larval control may offer a new alternative for effective control. Mosquito larval control strategies (environmental management and larviciding) have historically been shown to be successful in reducing the abundance of mosquitoes. This study plans to apply a larvicide in an effort to control malaria and reduce the burden of malaria. While it is abundantly clear that this product will kill mosquito larvae in the laboratory and in the field, it is not certain that doing so will reduce the burden of malaria for the human population. Briefly, the steps involved include survival and development of immature mosquito stages, emergence of adult mosquitoes, blood feeding by those mosquitoes, acquisition and development of malaria parasites by adult mosquitoes and transmission of parasites to susceptible humans. The objective of this pilot study is to evaluate the use of the time-to-infection end point as a measure of malaria transmission in The Gambia, while mosquito larvicides are used to control malaria vectors. The main outcomes of this study are (1) the proportion of adults with detectable parasitemia (Plasmodium falciparum) that is a binary variable and (2) time-to-infection with malaria parasites that will be treated as a continuous variable. This experimental design takes place over 7 months. The target sample size is 800 adults (aged 18-40 years, approximately half will be women and half men) living in 50 villages east of Farafenni town in The Gambia, West Africa. It is estimated that 552 of the adults will have no detectable parasites in their blood at the beginning of the transmission season (June). These parasite negative individuals will be followed either for the duration of the transmission season (June through November) or until they become positive for parasites.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to technology of chloropyramine hydrochloride-base preparations used in allergic dermatosis and allergic rhinitis. Method involves mixing active component with filling agents, talc and magnesium state, wetting granulation and the following tabletting. Potato starch and lactose are used as filling agents. Firstly, active component and lactose are ground in common in ratio 1 : (5-6) and then starch paste is added to prepared mixture in the amount 10-20 wt.% of total mixture amount. Mixture is granulated, dried and dried granulate is granulated again and prepared granules are powdered with magnesium stearate and talc. Sieve diameter of holes in the second stage of granulation is 30-60% of sieve diameter of holes in the first stage of granulation. Method provides elimination of chemical interaction of magnesium stearate with chloropyramine and granulation process is carried out for two stages. EFFECT: enhanced stability of composition, decreased hygroscopicity of tablets, simplified method of preparing. 1 tbl, 3 ex
Objective: Although studies have shown that digital measures of speech detected ALS speech impairment and correlated with the ALSFRS-R speech item, no study has yet compared their performance in detecting speech changes. In this study, we compared the performances of the ALSFRS-R speech item and an algorithmic speech measure in detecting clinically important changes in speech. Importantly, the study was part of a FDA submission which received the breakthrough device designation for monitoring ALS; we provide this paper as a roadmap for validating other speech measures for monitoring disease progression. Methods: We obtained ALSFRS-R speech subscores and speech samples from participants with ALS. We computed the minimum detectable change (MDC) of both measures; using clinician-reported listener effort and a perceptual ratings of severity, we calculated the minimal clinically important difference (MCID) of each measure with respect to both sets of clinical ratings. Results: For articulatory precision, the MDC (.85) was lower than both MCID measures (2.74 and 2.28), and for the ALSFRS-R speech item, MDC (.86) was greater than both MCID measures (.82 and .72), indicating that while the articulatory precision measure detected minimal clinically important differences in speech, the ALSFRS-R speech item did not. Conclusion: The results demonstrate that the digital measure of articulatory precision effectively detects clinically important differences in speech ratings, outperforming the ALSFRS-R speech item. Taken together, the results herein suggest that this speech outcome is a clinically meaningful measure of speech change.
Promoting cognition and reducing frailty in older Veterans with bright light therapy Frailty is a multifactorial syndrome characterized by vulnerability to stressors that increases disability and mortality risk. Thirty percent of Veterans 65 years or older are frail, which is three-times higher than aged matched non-Veterans. Frailty is intricately linked with cognitive impairment and Veterans are particularly susceptible with 14 percent exhibiting cognitive decline, some with early onset as young as 45 years of age. Importantly, 70% of frail and cognitively impaired older adults exhibit sleep disturbances, which makes identifying and improving sleep quality an attractive therapeutic strategy to enhance healthspan. Furthermore, this is of special interest as 55% of older Veterans experience sleep disturbances. The goal of this study is to examine the feasibility of utilizing bright light therapy (BLT) as a strategy to improve sleep via reduction of circadian rhythm disturbances. The long-term goal is to assess the potential for improving cognition and reducing frailty in older Veterans. BLT works by resynchronizing the hypothalamic biological clock via brief exposure to specific wavelengths of light following awakening, which restores melatonin and circadian rhythms. However, BLT has not been examined for reducing frailty in older Veteran populations. This project will therefore lay the foundation for larger trials the evaluate BLT in the treatment and prevention of cognitive disorders and to promote healthy aging.
PURPOSE:To provide an antitumor agent containing extract of Solanum lyratum as an active component. CONSTITUTION:Raw, dried or semi-dried leaves, stalks and/or whole grass of Solanum lyratum are leached at room temperature or extracted under heating with water, a water-soluble organic solvent (e.g. methanol, ethanol, etc.) or their mixture to obtain an extract of Solanum lyratum. The extract is used as an active component of the objective antitumor agent. The agent has excellent suppressing effect against various tumors, exhibits specific suppressing action even to Sarcoma 180 and JTC-26 and has extremely low toxicity. The extract is administered as it is or in the form of powder, granule, capsule or injection such as aqueous solution or suspension, etc., by oral administration or parenteral administration such as subcutaneous injection. The dose is 1g/ person daily for oral administration and 60mg/person daily for parenteral administration.
Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
Risk Summary

When pregnant rats and rabbits were administered ruxolitinib during the period of organogenesis adverse developmental outcomes occurred at doses associated with maternal toxicity (see Data). There are no studies with the use of Jakafi in pregnant women to inform drug-associated risks. 

The background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk in the U.S. general population of major birth defects is 2% to 4% and miscarriage is 15% to 20% of clinically recognized pregnancies.

Data

Animal Data

Ruxolitinib was administered orally to pregnant rats or rabbits during the period of organogenesis, at doses of 15, 30 or 60 mg/kg/day in rats and 10, 30 or 60 mg/kg/day in rabbits. There were no treatment-related malformations. Adverse developmental outcomes, such as decreases of approximately 9% in fetal weights were noted in rats at the highest and maternally toxic dose of 60 mg/kg/day. This dose results in an exposure (AUC) that is approximately 2 times the clinical exposure at the maximum recommended dose of 25 mg twice daily. In rabbits, lower fetal weights of approximately 8% and increased late resorptions were noted at the highest and maternally toxic dose of 60 mg/kg/day. This dose is approximately 7% the clinical exposure at the maximum recommended dose.

In a pre- and post-natal development study in rats, pregnant animals were dosed with ruxolitinib from implantation through lactation at doses up to 30 mg/kg/day. There were no drug-related adverse findings in pups for fertility indices or for maternal or embryofetal survival, growth and development parameters at the highest dose evaluated (34% the clinical exposure at the maximum recommended dose of 25 mg twice daily).
BACKGROUND: H2S imbalances in the intestinal tract trigger Crohn's disease (CD), a chronic inflammatory gastrointestinal disorder characterized by microbiota dysbiosis and barrier dysfunction. However, a comprehensive understanding of H2S generation in the gut, and the contributions of both microbiota and host to systemic H2S levels in CD, remain to be elucidated. This investigation aimed to enhance comprehension regarding the sulfidogenic potential of both the human host and the gut microbiota.
RESULTS: Our analysis of a treatment-naive CD cohorts' fecal metagenomic and biopsy metatranscriptomic data revealed reduced expression of host endogenous H2S generation genes alongside increased abundance of microbial exogenous H2S production genes in correlation with CD. While prior studies focused on microbial H2S production via dissimilatory sulfite reductases, our metagenomic analysis suggests the assimilatory sulfate reduction (ASR) pathway is a more significant contributor in the human gut, given its high prevalence and abundance. Subsequently, we validated our hypothesis experimentally by generating ASR-deficient E. coli mutants ∆cysJ and ∆cysM through the deletion of sulfite reductase and L-cysteine synthase genes. This alteration significantly affected bacterial sulfidogenic capacity, colon epithelial cell viability, and colonic mucin sulfation, ultimately leading to colitis in murine model. Further study revealed that gut microbiota degrade sulfopolysaccharides and assimilate sulfate to produce H2S via the ASR pathway, highlighting the role of sulfopolysaccharides in colitis and cautioning against their use as food additives.
CONCLUSIONS: Our study significantly advances understanding of microbial sulfur metabolism in the human gut, elucidating the complex interplay between diet, gut microbiota, and host sulfur metabolism. We highlight the microbial ASR pathway as an overlooked endogenous H2S producer and a potential therapeutic target for managing CD. Video Abstract.
INTRODUCTION: Abnormal colour of plasma is infrequently identified during processing of blood and blood components. Common reasons include haemolysis, medications or diet related. Sometimes, the aetiology is unknown. It is a dilemma for every transfusion specialist encountering this situation. Effort should be made to find the aetiology of discolouration of plasma, so that the blood donor can be suitably advised, and a decision can be made regarding the use of blood products.
MATERIALS AND METHODS: We encountered two cases of orange coloured (amber coloured) plasma in our regular blood donors. All the common reasons for abnormal plasma discolouration were evaluated, including the donor's medication and diet. Spectrophotometry along with Liquid Chromatography-Mass Spectrometry (LC-MS) in both the positive and negative ion modes with literature search helped in arriving at a conclusion.
RESULTS: Haemolysis was ruled out by estimation of plasma haemoglobin. Spectrophotometric analysis of the coloured plasma samples showed a peak, which was absent in normal coloured plasma. This was further investigated using Liquid Chromatography-Mass Spectrometry (LC-MS) in both the positive and negative ion modes. There was no significant difference between the coloured and normal samples in the positive ion mode. But in the negative ion mode, there was a peak observed at 110.5 and 191 m/z value in the profile of the coloured samples in comparison with the normal sample. Literature review shows the peak was corresponding to the presence of quinic acid residues-a substance found in coffee, and potentially excreted into the plasma of an individual with high coffee consumption.
CONCLUSION: Reporting unusual causes associated with plasma discolouration is important. Present guidelines forbid issue of abnormal coloured blood and blood components for transfusion. Further such reports are necessary to confirm the safety of recipients receiving such units. This is the first case report to our knowledge of quinic acid discolouring blood products.
The invention provides a autism detection device based on a Gossip model, and belongs to the technical field of brain resting state functional magnetic resonance image processing. The invention sets Gossip model according to Gossip protocol and takes observation and measurement of the propagation performance of the structural network of autism patient group and normal contrast group as detection strategy. Comparing the calculation result of the detected person with the autism patient group and the normal control group respectively to determine the detection result of the detected person: and if the calculation result is closer to the first autistic patient group, the risk of the detected person suffering from the self-illness is high, otherwise, the risk of the current detected person suffering from the self-illness is low. The invention can be used for the preliminary diagnosis of autism of a subject of unknown type. Compared with a method for measuring topological properties of a global network and a local network, the Gossip model provided by the invention enables the difference of brain structures between a patient and a normal control group to be more obvious. The abnormal image can be identified more quickly and accurately, and diagnosis by doctors can be better assisted.
FIELD: chemistry. ^ SUBSTANCE: extraction is done using affinity chromatography with immobilised metal. The method can be realised in native conditions. Biologically active G-CSF is obtained with purity over 95%. Two more chromatography stages are done, cation-exchange and gel filtration, to remove trace amounts of impurities. The method allows for obtaining G-CSF with high output and over 99% purity. ^ EFFECT: described method is especially suitable for industrial production of G-CSF. ^ 16 cl, 5 dwg, 5 ex
FIELD: medicine. SUBSTANCE: method involves forming melted mass containing the active ingredient. The device has calender with two molding rollers rotating in opposite directions. The rollers have recesses. The calender has at least one roller every recess of which is divided with at least one partition spreading to the molding roller surface to enable one to mold fissure groove. EFFECT: low cost method. 13 cl, 7 dwg
Cohort B includes patients with Triple Negative Breast Cancer (TNBC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
To provide a technique capable of preventing, ameliorating or treating infertility or reproductive dysfunction, or a technique capable of preventing, ameliorating, treating or suppressing testis dysfunction, sperm hypofunction or ovulation disorder.SOLUTION: Provided is a composition containing trigonelline for preventing, ameliorating or treating infertility or reproductive dysfunction. Also provided is a composition containing trigonelline for preventing, ameliorating or treating testis dysfunction, sperm hypofunction or ovulation disorder. Disorder may be infertility or reproductive dysfunction caused by men-side or women-side or male side or female side. Disorder may be caused by systemic heat stress or topical heat stress. The composition may be used for men/women or male/female. Disorder may be caused by summer heat stress.SELECTED DRAWING: None